Waters Podcast#3: Advances in glycan analysis - - BioPharm International

ADVERTISEMENT

Waters Podcast#3: Advances in glycan analysis



Add this Podcast feed to your media player

UPLC, QTof, HDMS, and more: A practical guide to the hottest techniques driving the future of biopharmaceutical science



Episode Number 3: Advances in glycan analysis

As firms increasingly invest in biopharmaceutical development, there is a widespread need to educate scientists in new technologies and approaches in this rapidly evolving industry. For maximum effectiveness in drug development, the application of new techniques can save time and development costs. In this podcast series, we’ll provide you with a firm knowledge of the latest technological innovations in LC and LC/MS that have been designed to address and advance the very specific needs of the many applications areas in the biopharmaceutical laboratory.

Through a variety of topics highlighting our latest scientific work, this series will help you gain a better understanding of key bio-focused LC, MS, and software advancements. Learn how these solutions have been adopted by industry leaders around the world and how easy it is to implement the tools that deliver faster, better answers relating to the character and quality of your biopharmaceuticals.


Beth Gillece-Castro, Ph.D.
Principal Applications Chemist,
Chemistry Operations
Waters Corporation
Milford, MA, USA
UPLC technology for the analysis of antibody glycopeptides
Biopharmaceutical applications by Waters: A focus on proteins
N-linked glycans of glycoproteins: A new column for improved resolution


Click here to go to the main podcast page >>>
blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Novartis Sells Influenza Vaccine Business to CSL for $275 Million
October 27, 2014
Author Guidelines

Click here